Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0757
D

Failure to Complete Monthly Medication Review for Antibiotic Use

El Cajon, California Survey Completed on 04-18-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to complete a monthly medication regimen review (MRR) for a resident who was receiving Rifaximin, an antibiotic prescribed for encephalopathy. The resident was admitted with a history of metabolic encephalopathy and had been on Rifaximin since the previous year. A review of the resident’s records showed that no MRR was conducted for the months of January through March, despite the ongoing use of the antibiotic. The Infection Control Prevention Nurse (ICPN) confirmed that the resident’s Rifaximin use was not tracked or reviewed as part of the antibiotic stewardship log, as the focus was only on residents with infections. The ICPN also acknowledged that there was no documentation of side effect monitoring or routine assessment of the medication’s appropriateness in the resident’s clinical chart. Further interviews revealed that the DON expected all antibiotics, both short-term and long-term, to be tracked and reviewed monthly for indication of use and inclusion in the care plan. The facility’s policy required thorough MRRs to prevent, identify, and resolve medication-related problems, but this was not followed for the resident in question. The lack of monthly review and monitoring for the continued use of Rifaximin resulted in a failure to ensure the resident’s drug regimen was free from unnecessary drugs, as required by facility policy and federal regulations.

An unhandled error has occurred. Reload 🗙